SHRXF (Sharp Therapeutics) Current Accrued Expense: $0.11 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHRXF Sharp Therapeutics Corp SHRXF
12 GF Score
Price $0.57
View Full Analysis

What is Sharp Therapeutics Current Accrued Expense?

Sharp Therapeutics SHRXF 12 Current Accrued Expense is $0.11 Mil as of Jun. 2026. GuruFocus rates SHRXF with a GF Score™ of 12/100.

Sharp Therapeutics's Current Accrued Expense for the quarter that ended in Jun. 2026 was $0.11 Mil.

Sharp Therapeutics's quarterly Current Accrued Expense increased from Sep. 2025 ($0.11 Mil) to Dec. 2025 ($0.21 Mil) but then declined from Dec. 2025 ($0.21 Mil) to Jun. 2026 ($0.11 Mil).

Sharp Therapeutics's annual Current Accrued Expense increased from Dec. 2023 ($0.21 Mil) to Dec. 2024 ($0.23 Mil) but then declined from Dec. 2024 ($0.23 Mil) to Dec. 2025 ($0.21 Mil).

Sharp Therapeutics Current Accrued Expense Related Terms

Sharp Therapeutics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Sharp Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sharp Therapeutics Current Accrued Expense Chart

Sharp Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Current Accrued Expense
0.21 0.23 0.21

Sharp Therapeutics Quarterly Data
Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 0.09 0.11 0.21 0.11
SHRXF
12GF Score
Sharp Therapeutics Corp SHRXF
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sharp Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $0.11 Mil mean?
Sharp Therapeutics (SHRXF) has a Current Accrued Expense of $0.11 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Sharp Therapeutics and its competitors.
Is Sharp Therapeutics' Current Accrued Expense too high?
Sharp Therapeutics' current Current Accrued Expense is $0.11 Mil. Overall, Sharp Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Sharp Therapeutics' Current Accrued Expense compare to VRTX and REGN?
Sharp Therapeutics' Current Accrued Expense of $0.11 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Sharp Therapeutics and its competitors. Sharp Therapeutics's current Current Accrued Expense is $0.11 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sharp Therapeutics stock overvalued right now?
Sharp Therapeutics (SHRXF) has a current Current Accrued Expense of $0.11 Mil. The current Current Accrued Expense is $0.11 Mil. Sharp Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Sharp Therapeutics (SHRXF), the current Current Accrued Expense is $0.11 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sharp Therapeutics Business Description

Address 2403 Sidney Street, Suite 264, Pittsburgh, PA, USA, 15203
Sharp Therapeutics Corp is a preclinical-stage drug discovery company developing therapeutics for genetic diseases. It has developed the patent-protected Disco discovery platform consisting of the CoreX biology, AlloChem chemistry, and Mine computational technologies to discover drugs that selectively activate the protein thats been altered by gene mutation. The company has targeted its discovery engine (Disco) to three hereditary disorders with high unmet need, which include Gauchers Disease, Familial Frontotemporal Dementia, and Niemann Pick Type-C. Its drug development pipeline consists of the following candidates: SEL-148, 721, SEL-148, 742, and SEL-145, 793. Geographically, the company's business operations are carried out in the United States of America.
12GF Score

Get the complete analysis for SHRXF

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.57
Price